At Memorial Sloan Kettering (MSK), we’re not only changing the way we treat cancer, but also the way the world thinks about it. By working together and pushing forward with innovation and discovery, we’re driving excellence and improving outcomes.
For the 28th year, MSK has been named a top hospital for cancer by U.S. News & World Report. We are proud to be on Becker’s Healthcare list as one of the 150 Great Places to Work in Healthcare in 2018, as well as one of Glassdoor’s Employees’ Choice Best Place to Work for 2018. We’re treating cancer, one patient at a time. Join us and make a difference every day.
At MSK, new scientific findings are readily translated into diagnostic procedures through IHC analyses. There is the need for rapid yet accurate generation of new and robust IHC protocols in a CLIA compliant fashion. The Department of Pathology has three separate laboratories, which perform IHC procedures:
(1) The development IHC lab, which develops all novel primary reagents and IHC procedures which are implemented in other IHC labs, including the development and validation of CLIA compliant LDTs (Laboratory Developed Tests) for the clinical IHC
(2) The clinical IHC lab, which performs IHC analysis in a CLIA setting serving the diagnostic needs of the department’s pathologist faculty
(3) The IHC core facility, which performs non-CLIA compliant immunohistochemical analysis as a paid service and in a research setting.
New CLIA-compliant IHC protocols need to be established first in the developmental IHC lab, then implemented in the clinical IHC lab with simultaneous availability in the IHC core lab for research purposes. The Assistant Manager of IHC Development unites and oversees the technical operation of all three immunohistochemical laboratories, under the direction of and in close collaboration with of the Director of Immunohistochemistry, IHC Medical Director, and Department of Pathology Chair, working closely with the surgical pathology laboratory manager, clinical IHC supervisor, Pathology Core Lab Head, and Director of IHC.
The Assistant Manager of IHC helps to formulate and implement strategic directions and goals for the operation and development of IHC-based techniques based on the analysis of current operations, anticipated needs, financial considerations, and innovative approaches. This role provides strategic and technical direction and leadership in defining and achieving IHC objectives while ensuring compliance with regulatory agencies. The Assistant Manager of IHC is responsible for the daily operations of the IHC development lab while coordinating the efforts of the CLIA and core labs to provide unified workflows and technical approaches across the pathology department.
The position oversees the development of novel assays for both research and clinical practice, ensuring consistency of quality across multiple platforms while helping to pursue the department's scientific projects and mission, including R&D activities, and clinical trial activities to advance the growth of immunohistochemistry at MSKCC.
MSK is an equal opportunity and affirmative action employer committed to diversity and inclusion in all aspects of recruiting and employment. All qualified individuals are encouraged to apply and will receive consideration without regard to race, color, gender, gender identity or expression, sexual orientation, national origin, age, religion, creed, disability, veteran status or any other factor which cannot lawfully be used as a basis for an employment decision.
Federal law requires employers to provide reasonable accommodation to qualified individuals with disabilities. Please tell us if you require a reasonable accommodation to apply for a job or to perform your job. Examples of reasonable accommodation include making a change to the application process or work procedures, providing documents in an alternate format, using a sign language interpreter, or using specialized equipment.